



Tarus Therapeutics seeks to initiate clinical trial of TT-10 (A2AR antagonist) in cancer patients

NEW YORK, NY, USA – March 10, 2021

Tarus Therapeutics Inc., an innovative biotechnology company developing adenosine receptor antagonists for cancer immunotherapy, today announced that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on March 5, 2021 to support the initiation of a clinical study of TT-10, an oral small molecule drug candidate targeting the Adenosine A2A receptor (A2AR).

The application includes extensive preclinical data on TT-10's biological activity and safety profile, as well as details on how the therapy would be manufactured and administered to trial participants.

If the IND application is allowed by the FDA, the Company plans to initiate a Phase 1a/1b study in the second quarter of 2021 to evaluate TT-10 in patients with advanced solid tumors both as a monotherapy and in combination with other anti-cancer agents.

“This IND submission is a key milestone for Tarus as we continue to advance our portfolio of adenosine receptor antagonists for cancer immunotherapy. This IND filing brings us one step closer to entering the clinic with our potentially best-in-class A2AR antagonist,” said Sushant Kumar, Ph.D., Chief Executive Officer, Tarus Therapeutics. “This is a very exciting moment for the Tarus team, and we look forward to guidance from the FDA on the clinical development of TT-10.”

About Tarus Therapeutics Inc.

Tarus is developing small molecule inhibitors of A2AR, A2BR, and Dual A2AR/A2BR inhibitors for cancer immunotherapy and select non-oncology indications. The Company has the most comprehensive portfolio of adenosine receptor antagonists in development, with both first-in-class and best-in-class programs. More information can be found at www.tarustx.com.

Contact:

Tarus Therapeutics, Inc.
Sushant Kumar, PhD
President & CEO
info@tarustx.com